Medartis Growth Strong, but Outlook and EBITDA Lag

Medartis Delivers Strong Growth but Cautious Outlook

Medartis reported second-half 2025 group sales of CHF 146.3 million, aligning with consensus expectations. The company achieved a robust full-year organic growth of 15.7 percent, with the second half contributing approximately 16 percent organic growth.

Despite strong sales, the company's second-half Core EBITDA reached CHF 26.8 million, falling slightly below the consensus of CHF 27.3 million. The full-year margin improved by 60 basis points to 18.4 percent.

Regional Performance and Strategic Investments

The EMEA region was a significant driver, posting 18.0 percent organic growth. In contrast, North American growth slowed to 13.4 percent due to distributor optimization efforts. Performance in APAC and LATAM showed growth of 13.3 percent and 10.4 percent, respectively.

Operating free cash flow decreased to CHF 9.3 million from CHF 32.1 million in the previous year, a change attributed to increased investments in production machinery in the US, Brazil, and Basel.

Acquisition and Future Projections

Medartis announced the strategic acquisition of CADskills, a Belgian company specializing in personalized implants and titanium printing. This move is set to enhance its product offerings.

For 2026, the company projects organic core sales growth of 16-18 percent and a core EBITDA margin in the high-teens. This forecast, factoring in foreign exchange and M&A impacts, implies total sales of approximately CHF 322-328 million.

Summary

Medartis demonstrates solid revenue growth and strategic expansion through its acquisition of CADskills. However, the market is weighing this against a slight miss on EBITDA, significantly lower operating cash flow due to investments, and a cautious outlook for 2026.

FAQ

Q: What were the key financial figures for Medartis in its recent report?
A: Medartis reported 2H25 sales of CHF 146.3 million, full-year organic growth of 15.7%, and a 2H Core EBITDA of CHF 26.8 million.

Q: What major strategic move did Medartis announce?
A: The company announced the acquisition of CADskills, a Belgian specialist in personalized implants, to bolster its upper extremity product line.

Q: What is the company's financial forecast for 2026?
A: Medartis expects 16-18% organic core sales growth and a core EBITDA margin in the high-teens at constant exchange rates.

Source: Investing.com